Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manu De Rycker

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Nature Communications|February 4, 2026
Decoding efficacy and resistance space at a drug binding siteSimone Altmann, Cesar Mendoza-Martinez, Melanie Ridgway, et al.
Bioorganic & Medicinal Chemistry Letters|August 15, 2018
2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' diseaseMichael G Thomas, Manu De Rycker, Ignacio Cotillo Torrejon, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2013
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assayManu De Rycker, Irene Hallyburton, John Thomas, et al.
Nature Reviews. Microbiology|February 28, 2017
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing needMark C Field, David Horn, Alan H Fairlamb, et al.
The Journal of Infection|November 1, 2025
Target product profile and discovery and development path for novel cryptococcal disease treatmentsDavid B Meya, Manu De Rycker, Ian H Gilbert, et al.
Nature Reviews. Microbiology|September 13, 2018
Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing needMark C Field, David Horn, Alan H Fairlamb, et al.
Molecular and Biochemical Parasitology|August 16, 2025
Biophysical analysis of an oligomerization-attenuated variant of the Leishmania donovani dynamin-1-like proteinEllen Wuyts, Ramasubramanian Sundaramoorthy, Lindsay Tulloch, et al.
The Journal of Biological Chemistry|December 5, 2024
Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitorsThomas C Eadsforth, Leah S Torrie, Paul Rowland, et al.
Journal of Medicinal Chemistry|September 30, 2015
Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma bruceiLaura A T Cleghorn, Sébastien Albrecht, Laste Stojanovski, et al.
RSC Medicinal Chemistry|July 2, 2025
Structure-activity relationships of 1,5-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]diazepine-2,4(3<i>H</i>)-diones as inhibitors of <i>Trypanosoma cruzi</i>Michael G Thomas, Joanne Dunne, Peter G Dodd, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Nature Communications|February 4, 2026
Decoding efficacy and resistance space at a drug binding siteSimone Altmann, Cesar Mendoza-Martinez, Melanie Ridgway, et al.
Bioorganic & Medicinal Chemistry Letters|August 15, 2018
2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' diseaseMichael G Thomas, Manu De Rycker, Ignacio Cotillo Torrejon, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2013
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assayManu De Rycker, Irene Hallyburton, John Thomas, et al.
Nature Reviews. Microbiology|February 28, 2017
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing needMark C Field, David Horn, Alan H Fairlamb, et al.
The Journal of Infection|November 1, 2025
Target product profile and discovery and development path for novel cryptococcal disease treatmentsDavid B Meya, Manu De Rycker, Ian H Gilbert, et al.
Nature Reviews. Microbiology|September 13, 2018
Author Correction: Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing needMark C Field, David Horn, Alan H Fairlamb, et al.
Molecular and Biochemical Parasitology|August 16, 2025
Biophysical analysis of an oligomerization-attenuated variant of the Leishmania donovani dynamin-1-like proteinEllen Wuyts, Ramasubramanian Sundaramoorthy, Lindsay Tulloch, et al.
The Journal of Biological Chemistry|December 5, 2024
Pharmacological and structural understanding of the Trypanosoma cruzi proteasome provides key insights for developing site-specific inhibitorsThomas C Eadsforth, Leah S Torrie, Paul Rowland, et al.
Journal of Medicinal Chemistry|September 30, 2015
Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma bruceiLaura A T Cleghorn, Sébastien Albrecht, Laste Stojanovski, et al.
RSC Medicinal Chemistry|July 2, 2025
Structure-activity relationships of 1,5-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]diazepine-2,4(3<i>H</i>)-diones as inhibitors of <i>Trypanosoma cruzi</i>Michael G Thomas, Joanne Dunne, Peter G Dodd, et al.
Pageof 5